The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor causes rapid lymph node shrinkage, along with an increase in lymphocytosis, prior to inducing objective responses in CLL patients. Th...
Main Authors: | Stefania Fiorcari, Wells S Brown, Bradley W McIntyre, Zeev Estrov, Rossana Maffei, Susan O'Brien, Mariela Sivina, Julia Hoellenriegel, William G Wierda, Michael J Keating, Wei Ding, Neil E Kay, Brian J Lannutti, Roberto Marasca, Jan A Burger |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3871531?pdf=render |
Similar Items
-
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
by: Simon Schliffke, et al.
Published: (2018-04-01) -
Grave diarrhea associated with idelalisib administration
by: David Suárez del Olmo, et al.
Published: (2016-05-01) -
Polymicrobial lung infection associated with idelalisib administration
by: Eva Lázaro-López, et al.
Published: (2018-01-01) -
The crusading expeditions of 1101-2
by: Mulinder, Alec C.
Published: (1996) -
Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.
by: William K Decker, et al.
Published: (2012-01-01)